Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1050
- Registration Number
- NCT06065748
- Locations
- 🇺🇸
Sutter Health Medical Center, Sacramento, California, United States
🇩🇪Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie, Bamberg, Germany
🇬🇷Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 106
- Registration Number
- NCT06047184
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06016738
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
🇲🇾Clinical Trials Site, Sungai Petani, Kedah, Malaysia
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 60
- Registration Number
- NCT05963984
- Locations
- 🇺🇸
Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida, United States
🇺🇸Mfsmc-Hjwci, Baltimore, Maryland, United States
🇺🇸Saint Luke's Cancer Institute, Kansas City, Missouri, United States
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 135
- Registration Number
- NCT05933395
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05870579
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT05867251
- Locations
- 🇺🇸
NEXT Virginia, Fairfax, Virginia, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, Pennsylvania, United States
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 30
- Registration Number
- NCT05806671
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Scorpion Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05768139
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇮🇹Fondazione Policlinico Universitario A Gemelli-Rome, Roma, Lazio, Italy
🇮🇹Istituto Europeo di Oncologia, Milano, Lombardia, Italy
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT05759949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.